EFSA published a statement on the proposed testing strategy for assessing the ED properties of acibenzolar-S-methyl.
24th April 2023
EFSA Statement on acibenzolar-S-methyl ED testing programme
24April
13th December 2022
EFSA reports on ED properties amisulbrom
13December
EFSA published on 09.12.2022 a Technical Report on the potential ED properties of amisulbrom.
25th October 2022
EFSA conclusion flutianil ED confirmatory data
25October
EFSA published on 17.110.2022 its conclusions on the confirmatory data on ED properties of flutianil.
26th July 2022
Pyraclostrobin ED consultation
26July
EFSA opened a public consultation on the ED-updated RAR for pyraclostrobin.
8th July 2022
EFSA experts’ meeting agenda: ethephon
08July
EFSA published the agenda for one Peer Review Experts’ meeting in August 2022.
7th July 2022
EFSA consultation ED update RAR metrafenone
07July
On 07.07.2022 EFSA opened a public consultation on the updated RAR for metrafenone.
7th July 2022
EFSA consultation on ED update mepanipyrim
EFSA opened on 05.07.2022 a public consultation on the updated RAR for mepanipyrim.
5th July 2022
EFSA consultation ED properties dichlorprop-P
05July
EFSA opened a 2-month consultation on the updated RAR for dichlorprop-P.
30th June 2022
EFSA consultation ziram ED properties
30June
EFSA opened a consultation on the updated RAR for the AIR 3.4 substance ziram.
29th June 2022
EFSA consultation on metconazole ED update
29June
EFSA opened a public consultation on the updated RAR for metconazole.
21st June 2022
EFSA consultation ED properties mecoprop-P
21June
EFSA opened on 20.06.2022 a public consultation on the assessment of ED properties of mecoprop-P and mecoprop-P ethyl heptyl.
14th June 2022
EFSA consultation flufenacet ED
14June
EFSA opened on 31.05.2022 a public consultation on the ED properties of flufenacet.
12th June 2022
EFSA consultation updated RAR trinexapac-ethyl
12June
On 10.06.2022 EFSA opened a public consultation on the updated RAR for trinexapac-ethyl.
9th June 2022
Public Consultation on phenmedipham ED assessment
09June
On 08.06.2022 EFSA opened a public consultation on the revised RAR for phenmedipham, and the assessments following the stop-the-clock for endocrine disruption properties.
11th May 2022
EFSA consultations on dimethomorph & milbemectin ED assessments
11May
EFSA opened consultations on the ED assessments following a stop-the-clock, for milbemectin and dimethomorph.
29th March 2022
EFSA conclusion on confirmatory data thiabendazole
29March
EFSA published on 28.03.2022 its conclusion on confirmatory data submitted for thiabendazole.
23rd March 2022
EFSA report on flutianil ED confirmatory data
23March
EFSA published on 22.03.2022 a Technical Report on the risk assessment of flutianil confirmatory data on endocrine disruption.
13th October 2021
EFSA consultation ED assessment aluminium ammonium sulphate
13October
EFSA opened on 12.10.2021 a public consultation on an update of the RAR of aluminium ammonium sulphate.
2nd March 2021
EFSA consultation metiram
02March
On 01.03.2021 EFSA opened a public consultation on the RAR for metiram, as well as on a draft Art. 4.7 report and its underlying documents.
2nd February 2021
EFSA consultation asulam
02February
On 02.02.2021 EFSA initiated a consultation on the peer review of asulam..